Last reviewed · How we verify
Cellgram-ED
Cellgram-ED is a small molecule that targets the CD47/SIRPα axis to modulate the immune response.
Cellgram-ED is a small molecule that targets the CD47/SIRPα axis to modulate the immune response. Used for Metastatic solid tumors, Relapsed or refractory multiple myeloma.
At a glance
| Generic name | Cellgram-ED |
|---|---|
| Also known as | Autologous bone marrow derived mesenchymal stem cell |
| Sponsor | Pharmicell Co., Ltd. |
| Drug class | CD47/SIRPα inhibitor |
| Target | CD47 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the CD47/SIRPα interaction, Cellgram-ED aims to restore the ability of the immune system to recognize and eliminate cancer cells. This mechanism is thought to be particularly effective in treating various types of cancer.
Approved indications
- Metastatic solid tumors
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction
- Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously (PHASE2)
- Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cellgram-ED CI brief — competitive landscape report
- Cellgram-ED updates RSS · CI watch RSS
- Pharmicell Co., Ltd. portfolio CI